The Prince Charles Hospital Research Report 2007-2008 - Part ...
Medical Director of Cardiology and Director of
Cardiology Clinical Research Centre (CCRC):
Associate Professor Darren Walters
T: 07 3139 4710
F: 07 3139 4715
Senior Research Clinicians/Personnel:
Principal Investigators: Research
Associate Professor Darren Walters
Professor JHN Bett
Dr Russell Denman
Dr Rod Chua
Dr Matthew Pincus International Professional Linkages
Dr A Roati Massachusetts General Hospital:
Associate Professor Con Aroney Sujith Seneviratne; Fellow in CT imaging
Dr Sujith Seneviratne Andrew Mcann; Fellow in interventional Cardiology
Dr Christian Hamilton-Craig, History of the Research Unit:
Dr Rolf Gomes Associate Professor Con Aroney and Professor Nick
Tony Lai Bett originally started clinical trials with a nurse
John Sedgwick researcher more than 15 years ago.
Mahala Huderverdi When Associate Professor Darren Walters was
Akshay Mishra appointed Medical Director of Cardiology in 2004,
Brendan Bell he continued to support Cardiology Research by
Jonathon Ginns establishing the contemporary structure of the Clinical
Fellows: Cardiology Research Centre (CCRC) and becoming its
Research Coordinators (2007-2008):
T: 07 3139 4711
F: 07 3139 6140
University of Queensland
CSIRO Australian e-Health Center
Associate Professor Darren Walters
The Prince Charles Hospital Research Report 13
There are three main areas of clinical research that the
unit focuses on and these are :
• Cardiovascular device based trials which include
cardiac stents, and cardiac structural heart disease
devices such as Core Valve™.
• Pharmaceutical trials focusing on novel
Research • Electrophysiology and pacing
The Clinical Cardiology Research Centre has
weekly meetings and is in one of the top enrolling
Centre trial sites in the country for cardiovascular trials.
The Centre has now assumed national leadership
of a number of trials including Saturn and the
Resolution Trial. We are independently financial
and turn over in excess of one million dollars per
inaugural Research Director. This has culminated in year in research funding.
the acquisition of space and equipment for its present
location. The trial centre has also been kindly supported by
a number of benefactors including Mr Lloyd Kyle-
Two Research Coordinator positions were established
by A/Professor Walters, which resulted in substantial Little who has contributed to the research unit on
increase in Clinical Trials for the research centre. an annual basis for the last four years. We have
also been the benefactor of the Vellnagel Family
necessitating an expansion of the staffing complement
to two full time Senior Research Coordinators, three
Current Research Projects:
The following trial includes a selection of just some of
the industry sponsored and investigator driven clinical
research studies conducted by the Cardiology Clinical
Australian CareLink Quality and Impact of RemotE
The ACQUIRE study will be an observational study,
designed to evaluated the use of the CareLink remote
monitoring device. This device will allow patients
who have had a pacemaker or an ICD (Internal
Cardiac Defibrillator) implanted, to be able to transfer
data from their device back to the hospital via the
It is hoped that this system would operate routinely for
those patients who live too far away from a hospital to
conveniently attend a clinic for interrogation of their
pacemaker or ICD. This would be time saving for the
patients, and cost saving for Queensland Health (as the
referring hospitals currently pay for patients to travel
full time Research Coordinators and a Research
back to TPCH for clinics).
Administrative Officer. The Center is closely affiliated
with Dr Michael Ray, Director of the Haemostasis Researchers: R. Denman; D. Walters; M. Adsett;
Research Laboratory and works collaboratively on V. Deen; P. Martin; T. Christensen
several investigator initiated research projects.
14 The Prince Charles Hospital Research Report
A multi-centre clinical registry of BioMatrix drug -
eluting stent in Asia-Pacific countries.
A prospective, multi-centre, observational, patient
data registry program compiling data on patients
receiving the BioMatrix Stent with the objective of
assessing clinical outcomes in patients receiving the
BioMatrix DES Stent during treatment of Real World,
All-comer Patients. The primary endpoint for the study
is Major Adverse Cardiac Events (MACE) defined as a
composite of cardiac death, myocardial infarction (Q
and Non Q wave), or ischaemia driven Target Lesion
Revascularisation (TLR) at 12 months. Secondary
endpoints consist of safety and efficacy data. The
registry intends to enrol approximately 1000 patients
from up to 15 participating centres within Singapore,
Malaysia, Indonesia, New Zealand, Australia and Patients will be approached prior to their angiogram/
Thailand. Up to the first 20 patients per site (total of angioplasty procedure and given information
250) enrolled in the registry will have angiographic regarding the trial. If these patients have a blockage
assessment at the 9 month follow-up visit to assess in a coronary artery that is suitable for inclusion in
efficacy secondary endpoints. Other follow-up includes the trial, they will be randomised and treated with the
clinic visits at 30 days, 6 months, 12 months with ECG allocated device.
and phone contact at 90 days and 2 - 5 years annually.
COREVALVE INTERNATIONAL REVALVING REGISTRY:
Researchers: D. Walters PERCUTANEOUS AORTIC VALVE REPLACEMENT (PAVR)
CAP PROJECT: WITH THE COREVALVE REVALVING SYSTEM.
Information and Computer-based technologies
for Secondary Prevention of CVD in Community
Care Settings Care Assessment Platform Project,.
Collaboration with the Australian Center for eHealth.
This is project funded in excess of $ 500 000 and is a
collaboration between Q Health and CSIRO that aims
to show evidence that ICT enabled home-based care
process of cardiac rehabilitation patients provides
equally good or better outcomes than traditional
hospital based rehabilitation processes not using
Researchers : D Walters, A Fairfull, A Sarela, Mohanraj
Karunanithi. Core valve percutaneous aortic valve replacement
CARE II: Aortic valve disease consist of aortic stenosis and aortic
A prospective, randomized, multicentre study to regurgitation. Accounting for the vast majority of aortic
evaluate the safety, efficacy and performance of the valve disease, aortic stenosis prevalence is between
CardioMind Coronary Stent Systems for treatment 1% and 2% in the over 65 year old population and
of stenotic lesions in small diameter native coronary approximately 4% in the over 85 year old population. It
arteries. is mainly calcific stenosis due to senile degeneracy.
This trial will evaluate the CardioMind “Sparrow” The ineluctable development of the disease leads to
Coronary Artery Stents, in small narrowed coronary need for (surgical) valve replacement with a mechanical
blood vessels. The major benefit of these stents is they or a biological prosthesis (heterograft or allograft).
are self expanding and do not require dilation with a Today’s standard of care for heart valve replacement
balloon. This makes them thinner, more flexible, able requires open-heart surgery. During the operation,
to manoeuvre through tighter blockages and reach surgical access to the heart necessitates an incision
narrowings in more difficult positions. through the skin and muscle and requires the chest
cavity to be opened. At the time of the procedure, the
The Prince Charles Hospital Research Report 15
angina pectoris and moderate chronic kidney disease
undergoing percutaneous coronary intervention.
Cardiology DNB-001, the study drug, has been evaluated in
the laboratory, and has shown that it may have the
potential to protect against damage to the heart and
to the kidneys as might occur during Percutaneous
Coronary Intervention. The study will examine whether
it is safe to take the drug and whether the drug
can help prevent heart and kidney damage during
Research percutaneous coronary intervention.
Researchers: D. Walters; S. Seneviratne; M. Juneja; A.
Roati; JHN Bett; R. Chua; M. Pincus; R. Pincus
Centre ECG CHANGES FOLLOWING CARDIAC ARREST.
Patients admitted to hospital following cardiac arrest
are often considered for urgent coronary angiography
body’s circulation has to be maintained using extra- for exclusion of coronary artery disease. Whilst the
corporeal blood circulation. Then, the heart must be need for this in the setting of obvious cardiac ischaemic
stopped and the aorta opened to access the valve. The (typical ECG changes) is obvious, often the ECG
surgeon excises the defective valve and implants the changes are non-specific for cardiac ischaemia. To date
valve prosthesis. After heart activity resumes, the extra no study has attempted to document the ECG changes
corporeal circulation is discontinued and the chest is found in this patient population in the acute and
closed. General anaesthesia and cardiopulmonary subacute period following cardiac arrest.
bypass can lead to severe disorders of vital functions Researchers: D. Walters; R. Denman; J. Fraser; R.
(heart and lungs, brain, kidneys and liver) in the ageing Gomes
population, and ultimately, can result in death.
For these reasons, less invasive techniques have A randomised, double-blind, placebo-controlled study
emerged. Percutaneous procedures have been of the safety and tolerability of E5555 and its effects on
performed routinely for treatment of peripheral and clinical events and biomarkers in patients with non-ST-
coronary vascular disease for decades. They also segment elevation acute coronary syndrome.
have been used for acute valve disease; balloon
mitral and aortic valvuloplasties are performed as The primary objective of the study is to investigate
salvage procedures in non-operable patients with the safety and tolerability of E5555 at three dose
multiple high-risk or co-morbid conditions. A number levels in patients with acute coronary syndrome. The
of differing devices and techniques that could allow secondary objective is to determine the effect of E5555
for percutaneous treatment of mitral, pulmonary and on major adverse cardiac events as well as effect of
aortic valves (thus avoiding open-heart surgery) are E5555 on high-sensitivity C-Reactive Protein levels and
under development. effect of the study drug on marker of endovascular
Researchers: D. Walters; C. Aroney; P Pohlner and
CT CORONARY ANGIOGRAPHY IN THE ASSESSMENT
OF PATIENTS WITH CHEST PAIN:
An investigator driven study of the CT Coronary
angiography compared to standard chest pain
assessment service with exercise stress testing for
evaluating patients with chest pain.
Researchers; S Seneviratne, M Hansen, N Bett , D
Walters, J Ginns.
A phase IIa, multi-centre, double-blind, randomised,
placebo-controlled trial to evaluate the efficacy, safety
and pharmacokinetics of DNB-001 in patients with
Clement Lee, Senior Study Coordinator
16 The Prince Charles Hospital Research Report
Researchers: JHN Bett; D. Walters; R. Chua;
S. Seneviratne; T. Christensen.
An international study in which data will be collected of
patients who are suitable for stenting and who will be
treated with one or more drug eluting stents.
The primary objective of this study is to compare the
stent thrombosis rate of the Endeavour Zotarolimus
Eluting Coronary Stent System versus the Cypher
Sirolimus-eluting Coronary Stent in a patient
population requiring stent implantation. Participants
will be followed up for 5 years after the implantation
of the stent. Cardiac health will be assessed at a clinic
visit at 1 month and then patients will be contacted by
phone at 6 months. To check the blood flow through
the stent, the patient will have a repeat angiogram 8
months following the initial implant. They will again
have a clinic visit at 1 year and 2 years, then phone
follow-up continues annually until 5 years post implant. Patients will be randomised in a 1:1 fashion to either
placebo plus standard medical care (including aspirin
Researchers: D. Walters; M. Pincus; A. Roati; R. Chua; and clopidogrel) or to TRA (oral 40mg loading dose and
JHN Bett; S. Seneviratne; C. Lee a daily 2.5mg) once daily plus standard medical care.
SATURN: The primary endpoint of the TRACER trial is the
Study of coronary Atheroma by inTravascular composite of cardiovascular death, MI, stroke,
Ultrasound: effect of Rosuvastatin versus atorvastatin. rehospitalisation for recurrent ischaemia, or urgent
The primary objective of SATURN study is to compare coronary revascularisation. The study is event driven
the effects of rosuvastatin 40 mg with atorvastatin 80 and will be considered completed when the last
mg on the percent atheroma volume (PAV) as measured patient enrolled has been followed for 1 year and the
by intravascular ultrasound (IVUS) imaging following predefined number of endpoint events have been
104 weeks of treatment in patients with coronary artery achieved.
disease (CAD). Following 104 weeks of treatment in Researchers: JHN Bett; R. Chua; C. Lee.
patients with CAD, the secondary efficacy objectives
of the study are: (1) to determine whether rosuvastatin MPhil supervision Completed:
40 mg or atorvastatin 80 mg shows regression of PAV M Phil supervision completed
in the targeted coronary artery as measured by IVUS; Dr Michael Ray supervised Dr Darren Walters’ MPhil
(2) to compare the effects of rosuvastatin 40 mg with
atorvastatin 80 mg on the total atheroma volume of
the targeted coronary artery as measured by IVUS;
and (3) to compare the effects of rosuvastatin 40
mg with atorvastatin 80 mg on lipid and lipoprotein
metabolism. The safety objective is to assess the safety
and tolerability of rosuvastatin 40 mg and atorvastatin
80 mg during the 104 week treatment in patients with
Researchers: D. Walters; JHN Bett; R. Chua;
M. Pincus; S. Seneviratne; A. Small; A. Roati;
A multicentre, randomised, double-blind, placebo-
controlled study to evaluate the safety and efficacy of
SCH 530348 in addition to standard of care in subjects
with acute coronary syndrome: Thrombin Receptor
Antagonist for Clinical Event Reduction in acute
coronary syndrome (TRACER).
The Prince Charles Hospital Research Report 17
Cardiology Dr Tilak Sirisena’s current project involves using
CT coronary angiography in biomarkers for risk
stratification of patients undergoing non cardiac
There are also a series of collaborations within the unit.
Research Dr Walters collaborated with Natalie Kelly on her
project to determine outcomes following ASD closure in
the catheter lab. This project won the affiliate’s prize at
Centre the cardiac society annual scientific meeting 2007.
We are also currently collaborating with Dr Tau Boga
in Echocardiography Suite to write up the outcomes
for a septal occlusion closure device in the cardiac
Clinical Research Fellows: catheterisation laboratory.
Dr Andrew McCann
Dr Manjeet Junega Dr Walters’ Presentations:
Dr Tilak Sirisena
• Interventional Cardiology Conference, USA 2008
Dr Peter Larsen
• Asian Cardiac Interventional Therapeutics Program,
Dr Andrew McCann undertook research on Indigenous
health and rheumatic fever and subsequently • International Heart Forum in Beijing, China 2007
presented a paper entitled ‘Outcome for indigenous • Chinese Interventional Program, Hong Kong 2007
patients undergoing mitral valvuloplasty’ and • Euro PCR Barcelona 2007
compared this to a cohort of non-Indigenous patients • ANZET Symposium 2007-2008
over 10 years who underwent mitral valvuloplasty for • Kokura Live Program 2006 in Japan
rheumatic heart disease.
• Singapore Live 2005 & 2008,
His paper was presented at the Cardiac Society of • Annual Symposium at the University of Qld at Glen
Australia and New Zealand, subsequently the paper Eagles Kuala Lumpur
was published as a lead article in Heart, Lung and • University Medical College 2007
Circulation in February 2008.
• Update on Endeavour Trial Program Manila,
Dr Manjeet Juneja completed a clinical research Philippines, 2007
fellowship with us. He was from the Apollo Centre in • Rotary Humanitarian Mission in Rangoon, Burma,
Madras, India. His project was ”The use of Bivalirudin 2005-2007
versus Heparin in Patients with Acute Myocardial • Member of the International Liaison Committee on
Infarction.” The paper was presented at AHA and Resuscitation 2006-2008
Cardiac Society and he also presented his research at Peer reviewed and published manuscripts:
the Euro PCR conference in 2007.
Dr Juneja won a bronze medal for poster presentation • IIb or not IIb. J Am Coll Cardiol. 2008 Oct
at the Euro PCR conference and his paper has been 7;52(15):1277-8; author reply 1278. Mishra A,
submitted for publication in Euro Interventional Journal Walters D.
in 2008. • Invasive management and late clinical outcomes
in contemporary Australian management of
Dr Peter Larsen undertook research work on the
acute coronary syndromes: observations from
acute coronary syndrome project. a web based risk
the ACACIA registry. Med J Aust. 2008 June
stratification for ACS patients. His work with Margaret
16;188(12):691-7.Chew DP, Amerena JV, Coverdale
Dahl (ACS Coordinator) was presented at the ACHE
SG, Rankin JM, Astley CM, Soman A, Brieger DB;
conference at the Cardiac Society of Australia and New
Zealand annual scientific session 2008. This research
won the poster prize at the meeting.
18 The Prince Charles Hospital Research Report
• Percutaneous balloon mitral commissurotomy in
indigenous versus non-indigenous Australians.
Heart, Lung & Circulation. 17(3):200-5, 2008 June.
McCann, Andrew B. Walters, Darren L. Aroney, Con
• 2007 addendum to the National Heart Foundation
of Australia / Cardiac Society of Australia and
New Zealand Guidelines for the management of
acute coronary syndromes 2006.Medical Journal
of Australia. 188(5):302-3, 2008 March 3.Aroney,
Constantine N. Aylward, Philip. Chew, Derek P.
Huang, Nancy. Kelly, Anne-Maree. White, Harvey.
blood (2007). Clinical Orthopaedics and Related
• Variations in the application of cardiac care in Research, (456), pp. 238-242. Jong M.D., Ray M.,
Australia.Medical Journal of Australia. 188(4):218- Crawford S., Whitehouse S.L., Crawford R.W.
23, 2008 February 18.Walters, Darren L. Aroney,
Constantine N. Chew, Derek P. Bungey, Linden. • Trends in intra-aortic balloon counterpulsation:
Coverdale, Steven G. Allan, Roger. Brieger, David. comparison of a 669 record Australian dataset with
the multinational Benchmark Counterpulsation
• Treatment options and strategies for acute Outcomes Registry. Anaesth Intensive Care. 2007
severe pulmonary embolism.Intern Med J. 2008 Feb;35(1):13-9.Lewis PA, Mullany DV, Townsend S,
Aug;38(8):657-67.Hamilton-Craig CR, McNeil K, Johnson J, Wood L, Courtney M, Joseph D, Walters
Dunning J, Walters DL, Slaughter R, Kermeen F. DL.
• Telmisartan, ramipril, or both in patients at high • Easier, more effective, evidence-based guidelines
risk for vascular events.N Engl J Med. 2008 Apr for resuscitation: understanding the changes to
10;358(15):1547-59. Epub 2008 March 31.Yusuf S, the Australian Resuscitation Guidelines 2006.Heart
Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Lung Circ. 2007 Feb;16(1):2-6. Epub 2006 December
Dagenais G, Sleight P, Anderson C. 18. Walters D.
• Improvement after Angioplasty and Stenting of • Interventional Practice In Australia and New
Pulmonary Arteries Due to Sarcoid Mediastinal Zealand – Current Trends. Indian Heart Journal
Fibrosis – A Case Report.Heart Lung Circ. 2008 .2007: 59:2 suppl B16-20.Juneja, M. S., Walters,
Mar 28. Hamilton-Craig CR, Slaughter R, McNeil K, D.L.,
Kermeen F, Walters DL.
• Comparison of abciximab with “high-dose”
• Patient delay in responding to symptoms of tirofiban in patients undergoing percutaneous
possible heart attack: can we reduce time to care?. coronary intervention.International Journal of
Medical Journal of Australia. 187(5):293-8, 2007 Cardiology. 109(1):16-20, 2006 Apr 28.Gunasekara,
Sep 3.Finn, Judith C. Bett, John H Nick. Shilton, Athula P. Walters, Darren L. Aroney, Con N.
Trevor R. Cunningham, Carol. Thompson, Peter L.
• Early invasive versus conservative strategies for
• Investigation of factors relating to unstable angina & non-ST-elevation myocardial
neuropsychological change following cardiac infarction in the stent era Cochrane Database of
surgery. Perfusion. 22(1):27-33, 2007 January. Systematic Reviews. 3:CD004815, 2006.Hoenig, M
Raymond, Paul D. Radel, Michael. Ray, Michael J. R. Doust, J A. Aroney, C N. Scott, I A.
Hinton-Bayre, Anton D. Marsh, Neville A.
• Increased CD40 ligand expression on platelets
• The next generation Endeavor stent: 4 month is associated with cardiovascular events after
clinical and angiographic results from the Resolute total hip arthroplasty. Journal of Thrombosis &
first-in-man trial. Eurointervention. 2007; 3:50-54. Haemostasis. 4(3):695-7, 2006 March.Ray, M J.
Meredith IT, Worthley S, Whitborn R, Walters D, Crawford, S A. Crawford, R W. Jabur, M K. Walters,
Popma J, Cutlip D, Fitzgerald P D L.
• Platelet and leukocyte activation in salvaged blood • Assessment of statistical change criteria used to
and the effect of its reinfusion on the circulating define significant change in neuropsychological
The Prince Charles Hospital Research Report 19
Cardiology • Platelet-monocyte aggregates predict troponin
rise after percutaneous coronary intervention and
Clinical are inhibited by Abciximab.International Journal
of Cardiology. 101(2):249-55, 2005 May 25.Ray, M
J. Walters, D L. Bett, J N H. Cameron, J. Wood, P.
Aroney, C N.
Research • Aprotinin and epsilon aminocaproic acid are
effective in reducing blood loss after primary
total hip arthroplasty - A prospective randomized
Centre double-blind placebo-controlled study. Journal
of Thrombosis and Haemostasis, 3 (7), 2005 pp.
1421-1427. Ray M., Hatcher S., Whitehouse S.L.,
Crawford S., Crawford R.
• Novel use of sildenafil in the treatment of
test performance following cardiac surgery. portopulmonary hypertension.Journal of Heart &
European Journal of Cardio-Thoracic Surgery. Lung Transplantation. 24(4):498-500, 2005 April.
29(1):82-8, 2006 January.Raymond, Paul D. Hinton- Chua, Roderick,. Keogh, Anne. Miyashita, Masami.
Bayre, Anton D. Radel, Michael. Ray, Michael J. • Measurement of myocardial fractional flow
Marsh, Neville A. reserve is a cost-effective way to identify coronary
• Intracardiac echo guided valvuloplasty of a artery lesions of indeterminate severity that
stenotic tricuspid prosthetic valve in a patient warrant revascularisation.Heart Lung Circ. 2005
with idiopathic hypereosinophilic syndrome. Dec;14(4):239-41. Epub 2005 August 10.Trivedi S,
Echocardiography. 2006 Apr;23(4):324-8.Burstow Aroney CN, Walters DL, Bett JH.
DJ, West ML, Walters DL. • Balloon aortic valvotomy in pregnancy.
• Platelet-monocyte aggregates predict troponin • Aust N Z J Obstet Gynaecol. 2004 December
rise after percutaneous coronary intervention and ;44(6):577-9. Radford DJ, Walters DL.
are inhibited by Abciximab.International Journal
of Cardiology. 101(2):249-55, 2005 May 25.Ray, • Point-of-care testing shows clinically relevant
M J. Walters, D L. Bett, J N H. Cameron, J. Wood, P. variation in the degree of inhibition of platelets
Aroney, C N. by standard-dose abciximab therapy during
percutaneous coronary intervention.Catheter
• Acute Coronary Syndrome Data Set Writing Group. Cardiovasc Interv. 2004 Jun;62(2):150-4.Ray MJ,
Acute Coronary Syndrome Data Set Working Group. Walters DL, Bett N, Cameron J, Wood P, Aroney C.
National data elements for the clinical management
of acute coronary syndromes.Medical Journal of • Partially anomalous pulmonary venous connection
Australia. 182(9 Suppl):S1-14, 2005 May 2.Chew, treated by interventional catheterisation. Cardiol
Derek P B. Allan, Roger M. Aroney, Constantine N. Young. 2004 April; 14(2):222-4.Walters DL, Radford
Sheerin, Noella J. DJ.
• Failure of current public educational campaigns • The effect of glycoprotein IIb/IIIa receptor inhibitor
to impact on the initial response of patients with on the microcirculation in patients undergoing
possible heart attack.Internal Medicine Journal. high-risk coronary stenting; a prospective,
35(5):279-82, 2005 May.Bett, J H N. Tonkin, A M. randomized study. J Thrombolysis. 2003 December;
Thompson, P L. Aroney, C N. 16(3):163-6.Wong P, Harding S, Inglessis I, Choi CJ,
Walters D, Chang Y, Gimelli G, Jang IK.
• Measurement of myocardial fractional flow reserve
is a cost-effective way to identify coronary artery • Major pulmonary embolism and shock. Persistent
lesions of indeterminate severity that warrant hypotension after thrombolysis treated with
revascularisation.Heart, Lung & Circulation. improvised mechanical fragmentation of thrombus.
14(4):239-41, 2005 Dec.Trivedi, Shailendra. Aroney, Med J Aust. 2003 November 3;179(9):495-6.
Constantine N. Walters, Darren L. Bett, John Hugh Lapanun W, Walters DL, McCarthy J, Burstow DJ.
Nicholas • Coronary stenting for a muscular bridge in a patient
with hypertrophic obstructive cardiomyopathy.
20 The Prince Charles Hospital Research Report
Cardiol Young. 2003 August: 13(4):377-9.Walters
DL, Aroney CN, Radford DJ.
• Transthoracic left ventricular puncture for the
assessment of patients with aortic and mitral valve
prostheses: the Massachusetts General Hospital
experience, 1989-2000.Catheter Cardiovasc Interv.
2003 April; 58(4):539-44.Walters DL, Sanchez
PL, Rodriguez-Alemparte M, Colon-Hernandez PJ,
Hourigan LA, Palacios IF
• Acute coronary syndrome is a common clinical
presentation of in-stent restenosis.Am J Cardiol.
2002 March 1;89(5):491-4.Walters DL, Harding SA,
Walsh CR, Wong P, Pomerantsev E, Jang IK.
• The use of mechanical devices as adjuncts to • Congenital Long QT Syndrome: Management;
intracoronary stenting.Curr Opin Cardiol. 2001 Outcomes and the Role of Cardiac Transplantation.
September; 16(5):300-5. Walters DL, Harding SA, Heart Lung Circ. (formerly Asia Pacific Heart
Palacios IF, Oesterle SN. Journal). 1999;8:161-164Walters D, Masterson , ML,
• Adjunctive pharmacotherapy for coronary stenting.
Curr Opin Cardiol. 2001 September; 16(5):293-9.
Harding SA, Walters DL, Palacios IF, Oesterle SN.
• Vascular complications after hemostatic puncture
closure device (Angio-Seal) are not higher in
overweight patients.J Invasive Cardiol. 2001
September; 13(9):623-5.Wong P, Harding S, Walters
D, Hull ML, Jang IK.
Associate Professor Con Aroney , Professor Jean Claude Laborde and Associate Professor Darren Walters with a Core Valve implant.
The Prince Charles Hospital Research Report 21
Centre for Professional Linkages:
CDAS is the research centre for the Alcohol and
Drug Service and has links with the World Health
Drug & Alcohol
Organisation (WHO), the Australian National Council
on Drugs (ANCD), the University of Queensland, Griffith
University and Queensland University of Technology.
Ms Donna Simpson
Ms Wendy Ducat
Mr Jonathon Lee
Mr Robert Assan
Mr Wilson Mapinga
History of the Research Unit:
The Centre for Drug and Alcohol Studies (CDAS) is a
multi-disciplinary research, education and training
team. The purpose of CDAS is to develop, design
and implement novel research, to trial clinical
interventions, evaluate relevant state policy and
program initiatives and to design, develop and deliver
innovative education and training.
Conduct state-wide clinical research projects of critical
clinical importance across Queensland Health, with
outcomes influencing clinical processes, standards
of clinical practice and State and National population
health strategies and interventions
(l to r): Jonathon Lee and Robert Assan Design, disseminate and evaluate novel clinical
interventions for use with people with drug use
Alcohol and Drug Services: problems, including those with identified special
Name of General Research Area: needs including Indigenous populations and young
Alcohol, tobacco and other drug use and related issues people.
Alcohol and Drug Services: Provide expert counsel on research and development
Clinical Director: and quality improvement activities for the ADS and
Dr Jeremy Hayllar State-wide alcohol tobacco and other drugs sector.
Major Research Highlights:
Alcohol and Drug Services: CDAS was a Collaborating Centre for a World Health
Program Manager: Organisation study examining brief interventions with
Mr Mark Fairbairn alcohol misuses in 14 countries. The project produced
the internationally recognised AUDIT screen for alcohol
Statewide Services Program Manager: misuse and an related brief intervention.
Dr Carla Schlesinger
The development and validation of the Indigenous
Centre for Drug and Alcohol Studies (Research) Risk Impact Screen. IRIS is the first Indigenous specific
Program Coordinator: screen for mental health and alcohol and other drug
Ms Jane Fischer use.
T: 3837 5715 The evaluation and dissemination of SmokeCheck,
E: Jane_Fischer@health.qld.gov.au a smoking cessation brief intervention and training
Address and Affiliations: package. Over 800 health workers Statewide have now
Level 4, been trained in SmokeCheck.
‘Biala’ City Community Health Service,
270 Roma Street, Brisbane, QLD 4000
22 The Prince Charles Hospital Research Report
Current Research Projects:
IRIS Screen and Brief Intervention: Indigenous Risk
Impact Screen and Brief Intervention Project. The
training package is now currently being developed,
disseminated and evaluated.
Indigenous Smoking Cessation:
A smoking cessation brief intervention and training
package developed, disseminated and evaluated by
the Alcohol and Drug Service.
An action-research project to enhance capacity of
services and health staff directed at organisations,
teams, individuals and communities
Pharmaceutical Misuse: Clinical Trials:
As part of a national collaboration, the purpose of The long term outcome of patients undergoing valve
this project is to conduct research in on patterns surgery for bacterial endocarditis where intravenous
of pharmaceutical misuse and harms by clients drug use is the major risk factor: N. Blackwell; J.
undergoing detoxification, are in residential Hallyer; D. Mullany; P. Pohlner; A. Barnett; L. Munck.
rehabilitation or on opioid replacement therapy Infectious endocarditis is an extremely serious
programs. condition caused by micro-organisms growing in the
Nicotine Replacement Therapy: heart, damaging heart valves. Treatment often requires
Evaluation of Component Two of the Queensland surgical replacement of the affected valve(s). People
Health Smoking Management Policy: Provision of who self-inject with illicit drugs (heroin, speed) risk
Nicotine Replacement Therapy (NRT) to Inpatients endocarditis. Injecting drug us is a chronic, relapsing
disorder, these patients may be denied appropriate
Young People: therapy, even though data suggests they have a
AIMS is a structure method for developing rapport and similar prognosis to other patients with endocarditis.
speaking with young people about alcohol, tobacco Demonstrating good surgical outcomes will help
and other drug use. ensure patients receive the treatment they need.
Young People and Tobacco Smoking:
A Comparative Analysis of Tobacco Misuse Between
Indigenous and Non-Indigenous Teenagers:
Implications for Public Health Practice
An USA evaluated method for clinical practice
with clients, this project will be the first Australian
evaluation of mindfulness.
A whole of Alcohol and Drug Service project aimed at
identifying, implementing and evaluating treatment
outcome measures for use by alcohol and other drug
Masters Projects (current):
Mr Wilson Mapinga. A Comparative Analysis of Tobacco
Misuse Between Indigenous And Non-Indigenous
Teenagers: Implications for Public Health Practice
For a list of publications please contact CDAS
(L to R): Donna Simpson and Wendy Ducat
For a list of submissions please contact CDAS
The Prince Charles Hospital Research Report 23